RSV Seasonal Vaccine Introduction and Growth Strategy
Efficient delivery of profit attributable to shareholders
Q2 2022
£m
Q2 2023
Key commentary
£m
Operating profit (OP)
2,008
2,170
Net finance expense
(181)
(152)
+11% at CER (+12% at CER excluding COVID-19 solutions)
Higher interest income and lower bond interest costs;
[expect £700-750m in FY23]
Share of associates
(2)
Ταχ
(277)
(315)
Tax rate
15.2%
15.6%
Timing of tax settlements; expect ~15% rate in FY23
Non-controlling interests
(150)
(130)
Lower profit allocations to NCIs from ViiV Healthcare
Profit attributable to shareholders
1,398
1,571
Earnings per share (EPS)
34.7p
38.8p
+16% at CER (+17% at CER excluding COVID-19 solutions)
Total EPS
17.5p
40.1p
+>100% at CER
Weighted average number of shares (millions)
4,025
4,053
GSK
Adjusted results and for continuing operations unless stated otherwise
23
23View entire presentation